Physician profile
David Sedaghat
NPI 1538364112
$3,754.52
in general payments reported to CMS, 2019-2025
12 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $19.13 · 2021: $324 · 2022: $2,754 · 2023: $199 · 2024: $120 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.04 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $2,742.98 | 2022-2023 | Uptravi, Opsumit |
| Alnylam Pharmaceuticals INC. | $245.29 | 2021-2024 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $209.52 | 2025 | |
| Abbott Laboratories | $156.30 | 2019-2023 | Mitraclip |
| Medtronic, INC. | $124.94 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $110.59 | 2022 | |
| United Therapeutics Corporation | $51.81 | 2021 | |
| Braemar Manufacturing, LLC | $36.90 | 2019 | |
| Heartflow, INC. | $22.45 | 2021 | |
| Boston Scientific Corporation | $19.13 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.53 | 2019 | |
| Medtronic Vascular, INC. | $16.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sedaghat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.